and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...
In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best very cheap stocks to buy right now. The stock market had a mixed start to 2025 as the Chinese ...
Below is Validea's guru fundamental report for PFIZER INC (PFE). Of the 22 guru strategies we follow, PFE rates highest using our Earnings Yield Investor model based on the published strategy of ...
Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.
In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report). The company’s shares closed yesterday at $26.10. See what stocks are receiving ...
Fast forward to 2011, and GM has announced the sale of its $1 billion worth of Class A shares of Ally. The sale of the company's outstanding shares will allow the automaker to claim an additional ...
1 Day PFE 0.93% DJIA -0.13% S&P 500 -0.19% Health Care/Life Sciences 1.12% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results